Harvest volumes Q1 2026 (1)Farming Norway 75.5 thousand tonnes  Farming Scotland 20.5 thousand tonnes  Farming Chile 21.0 thousand tonnes  Farming Canada 8.0 thousand tonnes  Farming Ireland 2.0 thousand tonnes  Farming Faroes 3.0 thousand tonnes  Farming Iceland (Arctic Fish) 6.0 thousand tonnes  Total 136.0 thousand tonnes  Harvest volumes of 136 thousand tonnes versus 108 thousand tonnes in Q1 2025 are record-high for a first quarter, equivalent to a growth of 26%. In connection with the presentation of the Q4 2025 results, Mowi guided a total harvest volume of 128k GWT for Q1 2026. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWT). Additional information Operational EBIT for the Group was approx. EUR 221 million in Q1 2026 (NOK 2.52 billion, EURNOK 11.39). Blended farming cost was...

VANCOUVER, British Columbia, April 19, 2026 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today an update on the near-term operational plan related to the fire that occurred in certain areas of the crushing circuit at the Goose Mine in the evening of April 16, 2026, as described in B2Gold’s news release on April 17, 2026. The Company reconfirms that no injuries were reported and no medical treatment was required related to the fire. The Company can also confirm its initial assessment that the fire damage was localized to the crushing circuit area. There was no damage or impact to the mill or power facility. The Goose Mine currently has mobile crushers available at site and the preliminary operational plan is to utilize these mobile crushers to feed crushed ore directly...

ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA. These posters feature three of the Company’s drug candidates, Olverembatinib (HQP1351), a novel BCR-ABL inhibitor; APG-2449, a FAK/ALK/ROS1 triple tyrosine kinase inhibitor; and APG-5918, a PRC2/EED inhibitor. Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, said, “These preclinical findings...

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro’s platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR)...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department...

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physiciansVANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that KIMMTRAK® (tebentafusp-tebn)...

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT. “Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic oncology at UC...

MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic window MP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulationZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026. The first poster outlines preclinical...

Schneider ElectricSchneider Electric at Hannover Messe 2026HANNOVER, Germany, April 19, 2026 (GLOBE NEWSWIRE) — Industrial operations are under pressure from every direction. Energy costs are rising. Legacy systems are holding back progress. The talent pipeline is thinning. And the window to act is narrowing. At Hannover Messe 2026 (20–24 April, Hall 13, Booth C34), Schneider Electric, a global energy technology leader, is showing what it looks like when those problems finally meet their match. Across five live areas — Operational Efficiency, Legacy Drag, the Talent Gap, Data and Cybersecurity, and Energy Efficiency — Schneider Electric, AVEVA, ETAP, and ProLeiT are demonstrating how the convergence of electrification, open software-defined automation, and Industrial AI powered intelligence is already changing the economics...